AEROGEN
Following months of collaborative development work, Aerogen ® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006016/en/
The aerosolised vaccine is directly inhaled via a cup dispenser into the patient’s airway. This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia™ has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.1
Inoculation by the inhaled aerosol route requires a considerably smaller volume of vaccine to be used and therefore provides the capacity to allow a much larger number of patients to cost-effectively access the CanSinoBIO vaccine than would have been possible using an injectable approach.2
John Power, Aerogen CEO & Founder said “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination. The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”
Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO commented; “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery. The innovative development on the inhaled delivery of COVID-19 vaccine is the testimony of our collaborative efforts. It is demonstrated that the aerosolised vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass immune protection and accelerate the end of the pandemic. ”
CanSinoBio is preparing an application for commercial authorisation in China. Further clinical trials are in the process of being prepared for other countries.
Commercial terms of the partnership have not been disclosed.
Additional information:
About CanSinoBIO:
Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production, and commercialization of innovative vaccines for China and global public health security. It possesses five integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination, formulation, and mRNA. As of today, it has established a robust pipeline of 17 vaccines preventing 12 diseases, including the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021 and the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) approved in the same year.
About Aerogen:
Aerogen is the world leader in acute care aerosol drug delivery. The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology3
that mitigates the transmission of patient-generated infectious aerosol during ventilation4-9
. As the only globally available closed-circuit system, Aerogen technology has been used to treat over 14 million patients in 75 countries worldwide, playing a critical role in emergency departments and intensive care units10
.
References
- NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO’s COVID-19 Vaccine ConvideciaTM. http://www.cansinotech.com/html/1/179/180/651.html
- Heida R, Hinrichs WL, Frijlink HW. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19 [published online ahead of print, 2021 Aug 25]. Expert Rev Vaccines. 2021;1-18
- Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Revision U.
- Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir. Med. 2020; 167. doi:10.1016/j.rmed.2020.105987.
- Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID19 patients: A single center experience. J. Crit. Care. 2020; 58: 56–57.
- Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C et al. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020. doi:10.1089/jamp.2020.1615.
- Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.202009-3533SO.
- O’Toole C, McGrath JA, Joyce M, Bennett G, Byrne MA, MacLoughlin R. Fugitive Aerosol Therapy Emissions during Mechanical Ventilation: In Vitro Assessment of the Effect of Tidal Volume and Use of Protective Filters. Aerosol Air Qual Res 2020; 20. doi:10.4209/aaqr.2020.04.0176.
- Joyce M, McGrath JA, Mac Giolla Eain M, O’Sullivan A, Byrne M, MacLoughlin R. Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation. Pharmaceutics 2021; 13: 199.
- Aerogen internal data on File.
PM1087
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
Wizz Air Tops Major Airline Emissions Rankings2.7.2025 11:00:00 CEST | Press release
Cirium, the aviation analytics company, creates a new transparent standard and ranking for airline CO2 emissions, identifying the best performing airlines in specific categories Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments.
L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 10:59:00 CEST | Press release
Multi-year collaboration in LTTS’ Mobility segment to drive platform synergies, electrification, and innovation for TRATON GROUP L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration position
Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 10:30:00 CEST | Press release
Named Official Digital Wealth Platform of the DP World Tour through 2027 Nexo becomes Title Partner of the Nexo Championship, which takes place at Trump International Golf Links in August 2025 Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Champion
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 10:00:00 CEST | Press release
Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (follitropin delta); alongside its existing unique algorithm-based dosing Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 wome
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom